Tempus AI, Inc. , a technology company leading the adoption of AI to advance precision medicine, today announced that eight abstracts have been accepted for presentation at the 2026 ASCO® ...
BostonGene, the developer of the leading AI foundation model for tumor and immune biology, today announced a strategic collaboration with Ottimo Pharma Limited ("Ottimo"), an innovative, ...
AI Foundation Model for Tumor and Immune Biology to Guide Precision Patient Selection for Novel Bifunctional OTP-01 BostonGene, the developer of the leading AI foundation model for tumor and immune ...
Researchers shed light on the neural stem and progenitor cell (NSPC) microenvironment during development. Neurosphere formation from embryonic mouse forebrain NSPCs was significantly increased under ...
Researchers are targeting dormant tumour cells that might explain why some cancers reappear long after successful treatment.
Morning Overview on MSN
Baldness cure update: What studies now suggest
Hair loss has always been emotionally loaded, but the science behind it is becoming unusually exciting. A wave of new drugs, ...
There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback